Zymedyne is very pleased to announce that it has successfully secured a 2yr, $300k Alberta Innovates AICE Grant to pursue new compounds that target Zymedyne’s unique, non-opioid, pain relieving mechanism. This money will be used to create new compounds for patenting and to start independent testing of existing compounds in preliminary safety, tox, and bioavailability tests that are important for achieving IND designation
